Product details: YK-11 (Myostine) Liquid YK-11 (Myostine) Liquid contains the synthetic investigational compound YK-11, classified within the selective androgen receptor modulator (SARM) category. Structurally, YK-11 is distinct from many nonsteroidal SARMs due to its steroidal backbone, which contributes to its selective receptor interaction profile in experimental systems. This compound is commonly supplied in a liquid formulation, allowing for precise handling and controlled administration in laboratory environments. The liquid format supports consistent dispersion in experimental protocols and is intended strictly for in vitro studies and preclinical research models. Mechanism of Action In experimental models, YK-11 has been identified as a partial agonist of the androgen receptor (AR). When it binds to the receptor, it selectively activates AR-mediated transcriptional activity without causing the full activation profile seen with endogenous ligands [1]. At the molecular level, YK-11 has been shown in in vitro studies to increase the expression of follistatin, a regulatory protein involved in modulating myogenic signaling pathways. This effect is associated with altered transcriptional activity following AR binding, suggesting a unique mechanism of selective gene regulation [1]. These properties make YK-11 a valuable investigational compound for examining androgen receptor signaling, transcriptional modulation, and protein expression pathways in controlled laboratory environments. Properties of YK-11 (Myostine) Liquid : Molecular Formula: C₂₅H₃₄O₆ Molecular Weight: 430.5 g/mol CAS Number: 1370003‑76‑1 PubChem CID: 119058028 Synonyms: YK‑11, Myostine Research Applications/Benefits of YK-11 (Myostine) Liquid Androgen Receptor Signaling Studies YK-11 is utilized in experimental models to investigate selective activation of androgen receptors and their role in gene transcription. Its partial agonist activity allows researchers to study receptor-specific signaling pathways under controlled conditions [1]. Follistatin Expression and Regulatory Protein Analysis In vitro studies have demonstrated that YK-11 influences follistatin expression, making it a useful compound for examining regulatory proteins involved in cellular differentiation pathways and gene expression modulation [1]. Myogenic Pathway Investigation Researchers use YK-11 to explore signaling pathways associated with cellular differentiation processes. These investigations focus on transcriptional regulation and intracellular signaling mechanisms in muscle-related cell models without implying functional outcomes beyond controlled experimental observations [1]. Selective Androgen Receptor Modulation Research Due to its distinct structure, YK11 liquid serves as a model compound for studying how structural variations influence receptor binding and downstream signaling. This supports research into selective receptor modulation and pathway-specific activation in preclinical systems. Why choose Behemoth Labz to buy YK-11 Liquid? Choose Behemoth Labz, choose quality! We are among the few online sellers that believe in the integrity and purity of products. We offer YK-11 Liquid for sale, which is designed to meet the industrial criteria and the needs of researchers. Before launching our products, we test them through an independent laboratory to check their purity and ingredients. This procedure maximizes the accuracy and findings of your research experiments. Additionally, we deliver nationwide and internationally. We use a secure payment system that safeguards your personal information and prevents unauthorized third-party access. So, purchase YK-11 (Myostine) Liquid now and experience quality and purity for your research. Disclaimer: This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments. References: Kanno, Y., Ota, R., Someya, K., et al. “Selective androgen receptor modulator, YK11, regulates myogenic differentiation by follistatin expression.” Biological and Pharmaceutical Bulletin 36.9 (2013): 1460–1465.
